Abstract Our view of cancer and the immune system is that an immune deficiency/failure of immune surveillance results in immune dysregulation including a "hole" in the specificity repertoire that results in active tolerance (Tregs) to cancer antigens and common pathogens (Cell. Immunol. 1978). The genetic basis for cancer survival was described in the P815 mouse model for MHC linked IR-gene control (Williams, Dorf and Benacerraf, Ca. Res. 1974) and the method for application to man was described at AAI2012. At AAI2019 we described the Immunogenetic Theory of Cancer and Aging and defined the disease Acquired Immune Deficiency of Cancer. We described the fact that homozygosity at P2 of the leader peptide of HLA class I and at the NG2A NK cell receptor is associated with older age, longer survival after primary therapy for breast cancer and non-progression if HIV infection occurs. We showed that breast cancer survival is significantly longer among patients with higher numbers of NK cells at initial presentation for breast cancer treatment. Here we present data showing survival in colorectal cancer, just like in breast, is significantly better when NK cell numbers are higher at initial evaluation Presented also are data demonstrating that peripheral blood NK cell numbers decrease during radiation of the breast only to recover to baseline after XRT ends. There is little to no change in numbers of CD4+ cells and other immunological parameters. In colorectal cancer quantitative IgA are related to survival. This is not true in breast cancer. Quantitative IgM and IgG levels are not associated with survival in either breast or colorectal caner. We conclude that simple blood parameters can provide substantial insight about mechanisms of treatment in cancer survival.